CLAIMS

What is claimed is:

1. A compound of Formula (I):



(I)

or stereoisomers, tautomers, or salts thereof.

2. The compound according to claim 1, or stereoisomers or tautomers thereof.

3. The salt of the compound according to claim 1, or stereoisomers or tautomers thereof.

4. The pharmaceutical salt of the compound according to claim 1, or stereoisomers or tautomers thereof.

5. The compound according to claim 1, or stereoisomers, tautomer, or salts thereof, having the structure:



.

6. A pharmaceutical composition comprising a compound according to any one of claims 1-5, or stereoisomers, tautomers, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

7. A pharmaceutical composition comprising a compound according to claim 2, or stereoisomers or tautomers; and a pharmaceutically acceptable carrier.

8. A pharmaceutical composition comprising a pharmaceutical salt of the compound according to claim 4, or stereoisomers or tautomers thereof; and a pharmaceutically acceptable carrier.

9. A compound, or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, according to any one of claims 1 to 5 for use in therapy.

10. A compound, or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, according to any one of claims 1 to 5 for use in the treatment of cancer.

11. Use of a compound, or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 5 in the manufacture of a medicament for the treatment of cancer.

12. The compound, or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof for use according to claim 10 or the use according to claim 11 wherein said cancer

is selected from cancer of the colon, gastric, pancreatic cancer, breast cancer, prostate cancer, lung cancer, ovarian cancer, cervical cancer, renal cancer, cancer of the head and neck, lymphoma, leukemia, and melanoma.

13. The compound, or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof for use according to claim 10 or the use according to claim 11 wherein said cancer is selected lymphoma, leukemia, and multiple myeloma.

14. The compound, or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof for use according to claim 10 or the use according to Claim 11 wherein a therapeutically effective amount of a second agent is to be further administered to said patient, wherein said second agent is selected from an antagonist of PD1/PD-L1 axis, an antagonist of CTLA4, a chemotherapeutic agent, radiation, or an anti-tumor vaccine, prior to, simultaneously with or after administration of said compound.

15. Use of a compound, or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 5 in the manufacture of a medicament for the treatment of cancer in a patient, wherein the compound, or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof is to be administered to said patient to decrease the Ikaros, Helios, Aiolos, and Eos protein levels.

16. The use according to Claim 15, wherein:

a) said Ikaros protein is the amino acid sequence encoded by SEQ ID NOs: 1, 2, 3, 4, 5, or 6;

b) said Helios protein is the amino acid sequence encoded by SEQ ID NOs: 7,8, 9, 10, or 11;

c) said Aiolos protein is the amino acid sequence encoded by SEQ ID NOs: 12, 13, 14, 15, 16, 17, 18, or 19; and

d) said Eos protein is the amino acid sequence encoded by SEQ ID NOs: 20 or 21.

17. The use according to claim 15, wherein

a) said Ikaros protein level is decreased by at least 30 %;

b) said Helios protein level is decreased by at least 50 %;

c) said Aiolos protein level is decreased by at least 30 %; and

d) said Eos protein level is decreased by at least 50 %.

18. The use according to claim 15, wherein a therapeutically effective amount of a second agent is to be further administered to said patient, wherein said second agent is selected from an antagonist of PD1/PD-L1 axis, an antagonist of CTLA4, a chemotherapeutic agent, radiation, or an anti-tumor vaccine, prior to, simultaneously with or after administration of said compound.

19. A compound, or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 5 for use in decreasing Ikaros, Helios, Aiolos, and Eos protein levels in cells.